STOCK TITAN

IGC Pharma (NYSE: IGC) sells Holi Hemp assets in $2.7M agreement

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

IGC Pharma, Inc. reported that its wholly owned subsidiary Holi Hemp LLC, doing business as HH Processors, entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The Buyer will acquire equipment, inventory, and a ready-to-move facility and assume employee, utility, lease, and other operating obligations.

The parties agreed on a fair value of approximately $2.7 million, subject to an auditor’s valuation review. Holi Hemp will receive preferential supply rights, and if the Buyer disposes of the operating business within five years, Holi Hemp is entitled to 10% of the net proceeds from that sale, all subject to customary closing conditions and internal approvals.

Positive

  • None.

Negative

  • None.

Insights

IGC Pharma’s subsidiary is divesting operating assets in a structured $2.7 million deal with future upside rights.

The transaction moves equipment, inventory, and a ready-to-move facility of Holi Hemp LLC to Wellness Essentials Northwest Inc., with the Buyer taking over employees, utilities, lease obligations, and other operating expenses. The agreed fair value is approximately $2.7 million, pending an auditor’s valuation review.

Beyond the initial consideration, Holi Hemp retains economic ties through preferential supply rights and a contingent interest. If the Buyer sells the operating business within five years of the agreement date, Holi Hemp is entitled to 10% of the net proceeds from that sale. Completion depends on customary closing conditions and internal corporate approvals.

false 0001326205 0001326205 2025-10-01 2025-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 1, 2025

IGC PHARMA, INC.

(Exact name of registrant as specified in charter)

 

Maryland   001-32830   20-2760393
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

10024 Falls Road, Potomac, Maryland 20859

(Address of principal executive offices) (Zip Code)

 

(301) 983-0998

(Registrant’s telephone number, including area code)

 

 

 

(Former Name or Former Address, if Changed since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $.0001 par value   IGC   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company .

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On September 29, 2025, Holi Hemp LLC, dba HH Processors, a Maryland limited liability company (the “Seller”), and wholly owned subsidiary of IGC Pharma, Inc. (the “Company”), entered into a Sale of Assets and Manufacturing Agreement (the “Sale Agreement”), whereby Wellness Essentials Northwest Inc., a Washington corporation (“Buyer”) agreed to purchase equipment, inventory, and the ready-to-move facility of Seller and assumed the operational responsibilities for employees, utilities, lease obligations and other operating expenses, subject to the satisfaction of certain closing conditions. The parties agreed on a fair value of approximately $2.7 million for the transaction, which may be adjusted based on completion of the auditor’s valuation review.

 

The Buyer agreed to provide the Seller with certain preferential supply rights as set forth in the Sale Agreement. In the event that Buyer sells, transfers, or otherwise disposes of the operating business to a third party within a five-year period from the date of the Sale Agreement, Seller shall be entitled to receive 10% of the net proceeds received from Buyer in such sale. The obligations of the parties under the Agreement are subject to customary closing conditions, including receipt of internal corporate approvals and completion of the auditor’s valuation review.

  

The foregoing description of the Sale Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the Sale Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits

 

(d)        

 

Exhibit No.   Description
     
10.1   Sale of Assets and Manufacturing Agreement, dated September 29, 2025, by and between Holi Hemp LLC and Wellness Northwest Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

The exhibits listed in the following Exhibit Index are filed as part of this current report.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IGC PHARMA, INC.
     
Dated: October 1, 2025 By: /s/ Claudia Grimaldi
    Name:  Claudia Grimaldi
    Title: Principal Financial Officer and Vice President

 

2

FAQ

What transaction did IGC (IGC Pharma, Inc.) disclose in this 8-K?

IGC disclosed that subsidiary Holi Hemp LLC entered into a Sale of Assets and Manufacturing Agreement with Wellness Essentials Northwest Inc. The deal covers equipment, inventory, and a ready-to-move facility, with the Buyer also assuming various operating obligations associated with the business.

What assets of Holi Hemp LLC are being sold by IGC Pharma (IGC)?

The Buyer agreed to purchase Holi Hemp’s equipment, inventory, and a ready-to-move facility. In addition, Wellness Essentials Northwest Inc. will assume operational responsibilities, including employees, utilities, lease obligations, and other operating expenses tied to these assets and related activities.

What is the agreed value of the Holi Hemp asset sale by IGC (IGC)?

The parties agreed on a fair value of approximately $2.7 million for the Holi Hemp asset transaction. This amount may be adjusted after completion of the auditor’s valuation review, which is one of the customary conditions required before the transaction can close.

What ongoing rights does IGC’s Holi Hemp retain after the asset sale?

Holi Hemp will receive certain preferential supply rights from the Buyer, as detailed in the agreement. It is also entitled to 10% of the net proceeds if the Buyer sells, transfers, or otherwise disposes of the operating business within five years of the Sale Agreement date.

What contingent consideration could IGC (IGC) receive if the Buyer resells the business?

If Wellness Essentials Northwest Inc. sells, transfers, or otherwise disposes of the operating business within five years, Holi Hemp is entitled to 10% of the net proceeds from that sale. This creates a potential additional economic benefit beyond the initial agreed fair value.

What conditions must be satisfied before IGC’s Holi Hemp asset sale can close?

The obligations of both parties are subject to customary closing conditions. These include receipt of internal corporate approvals and completion of the auditor’s valuation review, which may result in adjustments to the approximately $2.7 million agreed fair value of the transaction.

IGC Pharma Inc

NYSE:IGC

IGC Rankings

IGC Latest News

IGC Latest SEC Filings

IGC Stock Data

27.09M
88.18M
Biotechnology
Pharmaceutical Preparations
Link
United States
POTOMAC